Tenon Medical (TNON) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 22% YoY and 12% sequentially; nine-month revenue grew 66%, gross margin improved, and operating loss narrowed.

• Q3 net loss increased, largely due to non-cash expenses below operating income.

• ~$15.6M in Q3 gross proceeds funded full repayment of senior convertible notes; quarter-end cash was $8.3M with no debt.

• Commercial priorities include expanding physician and distributor engagement, growing the sales force, and advancing product launches.

Financial highlights

• Q3 revenue was $1.432M versus $1.173M; nine-month revenue was $4.090M versus $2.463M.

• Q3 gross profit was $950,000 versus $773,000; nine-month gross profit was $2.709M versus $1.341M.

• Q3 operating expenses were $4.035M versus $4.165M; nine-month expenses were $12.428M versus $11.267M.

• Q3 operating loss improved to $3.085M from $3.392M; nine-month operating loss improved to $9.719M from $9.926M.

• Q3 net loss was $6.639M versus $3.339M; nine-month net loss was $14.165M versus $9.7M, primarily reflecting non-cash items below operating income.

Outlook and guidance

• Priorities include expanding physician training and adoption across both platforms, advancing the product pipeline, and maintaining spending discipline.

• Full market release of the Quickstep Decorticator is targeted for Q1 2027 after initial alpha cases.

• A SImmetry+ implant enhancement submission is anticipated in early December 2026.

• Plans include hiring direct sales representatives, onboarding independent distributors, and launching additional products over coming quarters.